REFERENCES
- Hammer SM, Eron JJ Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA Panel. JAMA. 2008;300(5):555–570.
- Clumeck N, Pozniak A, Raffi F. European AIDS Clinical Society (EACS) guidelines for the clinical manage-ment and treatment of HIV-infected adults. HIV Med. 2008;9(2):65–71.
- Yeni P. Prise en charge médicale des personnes infectées par le VIH. Rapport 2008. Recommandations du groupe d'experts. Paris; 2008.
- Pugliese P, Cuzin L, Enel P, et al. NADIS 2000, développement d'un dossier medical informatisé pour les patients infectés par VIH, VHB et VHC. Presse Med. 2003;32:299–303.
- Capetti AF, Piconi S, Landonio S, et al. Is dual therapy with raltegravir and protease inhibitors a feasible option in rescue strategy in HIV-1 infection? J Acquir Immune Defic Syndr 2009;50(2):233–234.
- Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008;358(20):2095–2106.
- Allavena C, Ferre V, Brunet-Francois C, et al. Efficacy and tolerability of a nucleoside reverse transcriptase inhibitor-sparing combination of lopinavir/ritonavir and efavirenz in HIV-1-infected patients. J Acquir Immune Defic Syndr 2005;39(3):300–306.
- Negredo E, Cruz L, Paredes R, et al. Virological, immu-nological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression. Clin Infect Dis. 2002;34(4):504–510.
- Podsadecki T, Tian M, Fredrick L, Lawal A, Bernstein B. Lopinavir/ritonavir (LPV/r) combined with raltegravir (RAL) provides more rapid viral decline than LPV/r combined with TDF/FTC in treatment-naïve HIV-1 infected subjects. HIV Med. 2009;10(Suppl):19–20.
- Eron J, Andrade J, Zajdenverg R, et al. Switching from stable lopinavir/ritonavir-based to raltegravir-based combination ART resulted in a superior lipid profile at week 12 but did not demonstrate non-inferior virologic efficacy at week 24. In: Program and abstracts from the 16th Conference on Retroviruses and Opportunistic Infections; February 8–11, 2009; Montreal, Canada. Abstract 70aLB.